Literature DB >> 19451302

In vitro activities of telavancin and vancomycin against biofilm-producing Staphylococcus aureus, S. epidermidis, and Enterococcus faecalis strains.

Kerry L LaPlante1, Leonard A Mermel.   

Abstract

We investigated the activities of telavancin and vancomycin against biofilm-producing Staphylococcus and Enterococcus strains. At clinically attainable concentrations, telavancin was active against bacteria embedded in biofilm (minimal biofilm eradication concentration [MBEC], 0.125 to 2 microg/ml) and inhibited biofilm formation at concentrations below the MIC. Vancomycin did not demonstrate the same activity (MBEC, > or =512 microg/ml) against Staphylococcus aureus and Enterococcus faecalis. Telavancin may have a unique role in biofilm-associated infections.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19451302      PMCID： PMC2704672          DOI： 10.1128/AAC.01642-08

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  27 in total

Review 1.  Guidelines for the management of intravascular catheter-related infections.

Authors:  L A Mermel; B M Farr; R J Sherertz; I I Raad; N O'Grady; J S Harris; D E Craven
Journal:  Clin Infect Dis       Date:  2001-04-03       Impact factor: 9.079

2.  A modified microtiter-plate test for quantification of staphylococcal biofilm formation.

Authors:  S Stepanovic; D Vukovic; I Dakic; B Savic; M Svabic-Vlahovic
Journal:  J Microbiol Methods       Date:  2000-04       Impact factor: 2.363

3.  The Calgary Biofilm Device: new technology for rapid determination of antibiotic susceptibilities of bacterial biofilms.

Authors:  H Ceri; M E Olson; C Stremick; R R Read; D Morck; A Buret
Journal:  J Clin Microbiol       Date:  1999-06       Impact factor: 5.948

4.  Hydrophobic vancomycin derivatives with improved ADME properties: discovery of telavancin (TD-6424).

Authors:  Michael R Leadbetter; Stacy M Adams; Bettina Bazzini; Paul R Fatheree; Dane E Karr; Kevin M Krause; Bernice M T Lam; Martin S Linsell; Matthew B Nodwell; John L Pace; Kelly Quast; Jeng-Pyng Shaw; Elizabeth Soriano; Sean G Trapp; Jenny D Villena; Terry X Wu; Burton G Christensen; J Kevin Judice
Journal:  J Antibiot (Tokyo)       Date:  2004-05       Impact factor: 2.649

5.  Quorum sensing in Staphylococcus aureus biofilms.

Authors:  Jeremy M Yarwood; Douglas J Bartels; Esther M Volper; E Peter Greenberg
Journal:  J Bacteriol       Date:  2004-03       Impact factor: 3.490

Review 6.  Resistance of bacterial biofilms to antibiotics: a growth-rate related effect?

Authors:  M R Brown; D G Allison; P Gilbert
Journal:  J Antimicrob Chemother       Date:  1988-12       Impact factor: 5.790

7.  Adherence of coagulase-negative staphylococci to plastic tissue culture plates: a quantitative model for the adherence of staphylococci to medical devices.

Authors:  G D Christensen; W A Simpson; J J Younger; L M Baddour; F F Barrett; D M Melton; E H Beachey
Journal:  J Clin Microbiol       Date:  1985-12       Impact factor: 5.948

8.  Comparative analysis of a biofilm-forming Staphylococcus epidermidis strain and its adhesion-positive, accumulation-negative mutant M7.

Authors:  F Schumacher-Perdreau; C Heilmann; G Peters; F Götz; G Pulverer
Journal:  FEMS Microbiol Lett       Date:  1994-03-15       Impact factor: 2.742

9.  Pharmacodynamics of telavancin (TD-6424), a novel bactericidal agent, against gram-positive bacteria.

Authors:  Sharath S Hegde; Noe Reyes; Tania Wiens; Nicole Vanasse; Robert Skinner; Julia McCullough; Koné Kaniga; John Pace; Roger Thomas; Jeng-Pyng Shaw; Glen Obedencio; J Kevin Judice
Journal:  Antimicrob Agents Chemother       Date:  2004-08       Impact factor: 5.191

10.  In vitro activity of telavancin against resistant gram-positive bacteria.

Authors:  Kevin M Krause; Marika Renelli; Stacey Difuntorum; Terry X Wu; Dmitri V Debabov; Bret M Benton
Journal:  Antimicrob Agents Chemother       Date:  2008-04-28       Impact factor: 5.191
View more
  22 in total

1.  Activity of pulmonary vancomycin exposures versus planktonic and biofilm isolates of methicillin-resistant Staphylococcus aureus from cystic fibrosis sputum.

Authors:  Nicholas S Britt; Daniel S Hazlett; Rebecca T Horvat; Rachael M Liesman; Molly E Steed
Journal:  Int J Antimicrob Agents       Date:  2020-01-11       Impact factor: 5.283

2.  Clinical and Genetic Risk Factors for Biofilm-Forming Staphylococcus aureus.

Authors:  Megan K Luther; Diane M Parente; Aisling R Caffrey; Kathryn E Daffinee; Vrishali V Lopes; Emily T Martin; Kerry L LaPlante
Journal:  Antimicrob Agents Chemother       Date:  2018-04-26       Impact factor: 5.191

3.  Telavancin shows superior activity to vancomycin with multidrug-resistant Staphylococcus aureus in a range of in vitro biofilm models.

Authors:  K Smith; C G Gemmell; S Lang
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-04-29       Impact factor: 3.267

Review 4.  Targeting bacterial membrane function: an underexploited mechanism for treating persistent infections.

Authors:  Julian G Hurdle; Alex J O'Neill; Ian Chopra; Richard E Lee
Journal:  Nat Rev Microbiol       Date:  2011-01       Impact factor: 60.633

5.  Evaluation of Telavancin Alone and Combined with Ceftaroline or Rifampin against Methicillin-Resistant Staphylococcus aureus in an In Vitro Biofilm Model.

Authors:  Seyedehameneh Jahanbakhsh; Nivedita B Singh; Juwon Yim; Warren E Rose; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2018-07-27       Impact factor: 5.191

Review 6.  A potential role for daptomycin in enterococcal infections: what is the evidence?

Authors:  Rafael Cantón; Patricia Ruiz-Garbajosa; Ricardo L Chaves; Alan P Johnson
Journal:  J Antimicrob Chemother       Date:  2010-04-02       Impact factor: 5.790

7.  In vitro activities of antibiotics and antimicrobial cationic peptides alone and in combination against methicillin-resistant Staphylococcus aureus biofilms.

Authors:  Emel Mataraci; Sibel Dosler
Journal:  Antimicrob Agents Chemother       Date:  2012-10-15       Impact factor: 5.191

Review 8.  Telavancin in the treatment of Staphylococcus aureus hospital-acquired and ventilator-associated pneumonia: clinical evidence and experience.

Authors:  Adamantia Liapikou; Katerina Dimakou; Michael Toumbis
Journal:  Ther Adv Respir Dis       Date:  2016-06-23       Impact factor: 4.031

Review 9.  Lipoglycopeptide Antibacterial Agents in Gram-Positive Infections: A Comparative Review.

Authors:  Françoise Van Bambeke
Journal:  Drugs       Date:  2015-12       Impact factor: 9.546

10.  A combined pharmacodynamic quantitative and qualitative model reveals the potent activity of daptomycin and delafloxacin against Staphylococcus aureus biofilms.

Authors:  Julia Bauer; Wafi Siala; Paul M Tulkens; Françoise Van Bambeke
Journal:  Antimicrob Agents Chemother       Date:  2013-04-09       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.